Jesus Berdeja, MD

Articles

Dr Berdeja on the Current Role of BCMA-Targeted Therapies in Multiple Myeloma

November 8th 2023

Jesus Berdeja, MD, discusses the current role of BCMA-targeted therapies in multiple myeloma, and imparts advice to colleagues regarding the sequencing of bispecific antibodies and CAR T-cell therapies.

Dr Berdeja on Ongoing and Planned Research Initiatives in Patients With Multiple Myeloma

October 26th 2023

Jesus Berdeja, MD, director, discusses ongoing and planned research initiatives in patients with multiple myeloma, specifically highlighting initiatives taking place at Tennessee Oncology.

Dr Berdeja on Patient Factors That Drive Treatment Decisions in Multiple Myeloma

October 18th 2023

Jesus Berdeja, MD, discusses factors to consider when choosing between CAR T-cell therapy and bispecific antibodies in patients with multiple myeloma.

Dr Berdeja on the Current Landscape of BCMA-Directed Therapies in Multiple Myeloma

October 7th 2023

Jesus Berdeja, MD, discusses the BCMA-directed CAR T-cell therapies and bispecific antibodies available for patients with multiple myeloma.

Dr. Berdeja on Updated CARTITUDE-1 Results in Multiple Myeloma

May 29th 2020

Jesus Berdeja, MD, discusses updated results from the ongoing phase 1b/2 CARTITUDE-1 trial (NCT03548207) in multiple myeloma.

Dr. Berdeja on Updated Data With bb21217 in Multiple Myeloma

March 31st 2020

Jesus Berdeja, MD, the director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses updated data with bb21217 in multiple myeloma.

Dr. Berdeja Discusses Anticipated Research in Multiple Myeloma

March 19th 2019

Jesus Berdeja, MD, the director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses anticipated research in the field of multiple myeloma.

Dr. Berdeja on Treatment of Patients With Newly Diagnosed Myeloma

February 13th 2019

Jesus Berdeja, MD, director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses the treatment of patients with newly diagnosed myeloma.

Dr. Berdeja on Maintenance Therapy in Multiple Myeloma

February 7th 2019

Jesus Berdeja, MD, director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses maintenance therapy in multiple myeloma.

Dr. Berdeja Discusses the Future of Treatment for Myeloma

February 24th 2018

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses the future of treatment for patients with myeloma.

Dr. Berdeja Discusses Response to CAR T-Cell Therapy bb2121

February 3rd 2018

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses response to the chimeric antigen receptor (CAR) T-cell therapy bb2121 in patients with multiple myeloma.

Dr. Berdeja Discusses Next Steps With bb2121 in Multiple Myeloma

January 27th 2018

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses next steps with the CAR T-cell therapy bb2121 in multiple myeloma.

Dr. Berdeja Discusses Study of bb2121 Anti-BCMA CAR-T Cell Therapy

January 3rd 2018

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses a study of bb2121, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy.